Cardiothoracic & vascular anesthesia

Antimicrobial Prophylaxis With Ampicillin-sulbactam Compared With Cefazolin for Esophagectomy: Nationwide Inpatient Database Study in Japan

Ann SurgPublished Retrospective cohort study

Authors' conclusion

The administration of ABPC/SBT as antimicrobial prophylaxis for esophagectomy was associated with better short-term postoperative outcomes compared with CEZ.

Study context

Population
Patients undergoing esophagectomy for cancer, Japan, July 2010–March 2019
Participants
17,772 eligible patients
Exposure
Ampicillin-sulbactam vs cefazolin antimicrobial prophylaxis
  • ABPC/SBTn = 1,695
  • CEZn = 16,077reference
Outcome
Short-term outcomes: SSI, anastomotic leakage, respiratory failure
Methodological detailsnationwide Japanese inpatient database, overlap propensity score weighting, sensitivity analyses: propensity score matching and instrumental variable analyses
  • Nationwide Japanese inpatient database
  • Overlap propensity score weighting
  • Sensitivity analyses: propensity score matching and instrumental variable analyses

Main finding

As reported in the abstract

SSI, anastomotic leakage, respiratory failure
ABPC/SBT vs CEZOdds ratio (95% CI)
SSI
0.51(0.43–0.60)
Anastomotic leakage
0.51(0.43–0.61)
Respiratory failure
0.66(0.57–0.77)
Surgical site infection (SSI) overall
2971 (16.7%)
Anastomotic leakage overall
2604 (14.7%)
Respiratory failure overall
2754 patients (15.5%)

Observational data: associations, not effects.

Further findings

ABPC/SBT associated with reduced respiratory complications, postoperative LOS and total hospitalization costs

Safety

Clostridioides difficile colitis and noninfectious complications

Proportion did not differ between the groups

Original publication

Antimicrobial Prophylaxis With Ampicillin-sulbactam Compared With Cefazolin for Esophagectomy: Nationwide Inpatient Database Study in Japan. Ann Surg. Published 15 December 2023. doi:10.1097/sla.0000000000006182

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.